Decision-making about gene therapy in transfusion dependent thalassemia
Abstract Background Hematopoietic stem cell transplantation (HSCT) is a treatment option with curative intent for patients with transfusion dependent thalassemia (TDT) but its application is limited by the lack of suitable donors and acceptability due to the related morbidity/mortality. Transplantat...
Main Authors: | Maa-Ohui Quarmyne, Diana Ross, Cynthia Sinha, Nitya Bakshi, Jeanne Boudreaux, Lakshmanan Krishnamurti |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | BMC Pediatrics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12887-022-03598-3 |
Similar Items
-
Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
by: Lauren M. Hawkins, et al.
Published: (2020-04-01) -
Impact of COVID-19 Pandemic on Pre-Transfusion Hemoglobin Level and Frequency of Transfusion in Transfusion-Dependent Thalassemia Patients in Indonesia
by: Ludi Dhyani Rahmartani, et al.
Published: (2022-12-01) -
Non-Transfusion-Dependent Thalassemia: A Panoramic Review
by: Hwazen Shash
Published: (2022-10-01) -
Proportion of Hypogonadism in Transfusion-Dependent Thalassemia Patients and Its Contributing Factors
by: Dian Anindita Lubis, et al.
Published: (2024-01-01) -
Mutational analysis of thalassemia in transfusion-dependent beta-thalassemia patients from central India
by: Manisha Shrivastava, et al.
Published: (2019-01-01)